Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
An innovation created by Purdue University researchers could improve therapy selection for personalized cancer care by helping specialists better identify the most effective drug treatment combinations for patients.
David D. Nolte, a professor in Purdue's Department of Physics, and his collaborators Ran An, a graduate student in physics, and John J. Turek in the Department of Basic Medical Sciences have created a technique called BioDynamic Imaging that measures the activity inside cancer biopsies, or samples of cells. It allows technicians to assess the efficacy of drug combinations, called regimens, on personal cancers.
"Technicians can use BioDynamic Imaging to measure tumor response to cancer therapy, such as metabolism and cell division. This can tell how well the drug is working and if there are side effects," Nolte said. "Our approach is called phenotypic testing, which is more pertinent than genetic testing because it captures the holistic response of cancer to chemotherapy."
BioDynamic Imaging tailors therapies to fit each cancer patient.
"No two cancers are alike," Nolte said. "Therefore, every patient needs his or her own selected therapy to get the best results."
Nolte said BioDynamic Imaging has other applications, including drug discovery and improving success rates for in vitro fertilization.
"BioDynamic Imaging is a new type of imaging that has broad uses and many applications," he said. "In IVF clinics, it can select the most viable embryos for implantation, improving pregnancy rates and decreasing the risk of having twins or triplets. It also can be used on a large scale to help search for new types of drugs."
Animated Dynamics LLC, based in the Purdue Research Park, is commercializing the BioDynamic Imaging technology. The company will manufacture the first commercial units for laboratories and clinics for testing and appraisal. The company won first place and $30,000 in the 2013 Burton D. Morgan Business Plan Competition.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cancer / Oncology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Purdue University. "Purdue innovation could improve personalized cancer-care outcomes." Medical News Today. MediLexicon, Intl., 16 Aug. 2013. Web.
6 Dec. 2013. <http://www.medicalnewstoday.com/releases/264890>
Purdue University. (2013, August 16). "Purdue innovation could improve personalized cancer-care outcomes." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/264890.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.